Previous 10 | Next 10 |
ALX Oncology (NASDAQ:ALXO) said the first patient was dosed in a phase 2/3 ASPEN-06 trial evaluating its drug evorpacept and Eli Lilly's (NYSE:LLY) Cyramza (ramucirumab), added to trastuzumab and paclitaxel to treat patients with HER2-positive gastric cancer or gastroesophagea...
SOUTH SAN FRANCISCO, Calif., March 02, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”), a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint mechanism, today announced the first patient ...
ALX Oncology press release (NASDAQ:ALXO): Q4 GAAP EPS of -$0.70 misses by $0.08. Cash and cash equivalents as of December 31, 2021 were $363.7 million. For further details see: ALX Oncology GAAP EPS of -$0.70 misses by $0.08
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today reported financial results for the fourth quar...
2 poor data announcements did not help the stock. LSV sold off a major chunk. ALXO is increasingly looking like an also-ran. For further details see: ALX Oncology Is Turning Into An Also-Ran In Anti-CD47
SOUTH SAN FRANCISCO, Calif., Jan. 27, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that the U.S. Food and Drug Administ...
Palm Beach, FL – January 20, 2022 – FinancialNewsMedia.com News Commentary – Despite significant progress in the treatment of gastric cancer, it is still among the leading causes of deaths due to cancer, across the world. The high mortality rates are pr...
SOUTH SAN FRANCISCO, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today provided a corporate update and highlighted ke...
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint pathway, today announced that Jaume Pons, Ph.D., Founder, Pres...
Indie Semiconductor (INDI -5.4%) shares plummets after the company disclosed a sale of shares by CFO Thomas Schiller. Thomas Schiller sold 200,00 shares of the company's common stock at $11.85 for $2.4M. Form 4 A look at INDI's ownership composition: For further details see: I...
News, Short Squeeze, Breakout and More Instantly...
ALX Oncology Holdings Inc. Company Name:
ALXO Stock Symbol:
NASDAQ Market:
ALX Oncology Holdings Inc. Website:
2024-07-09 15:54:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Evorpacept in combination with PADCEV ® , an approved antibody-drug conjugate (“ADC”), demonstrated promising activity and was generally well tolerated Company to host conference call and webcast with Samuel A. Funt, M.D., of Memorial Sloan Kettering Cancer Center on ...
SOUTH SAN FRANCISCO, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced that management wi...